Lynparza (olaparib) Approved for Ovarian Cancer


The United States Food and Drug Administration (FDA) has approved Lynparza (olaparib) for the treatment of advanced ovarian cancer.

The indication for which Lynparza is approved is ovarian cancer that has specific mutations in the BRCA genes, as detected by a specific test approved by the FDA called the BRACAnalysis CDx.

Lynparza works by inhibiting some enzymes (proteins) in cancer cells that repair DNA damaged by chemotherapy. It is referred to as a poly ADP-ribose polymerase (PARP) inhibitor.

The trial that prompted the approval of Lynparza included 137 women with ovarian cancer that had the gBRCAm mutation.

Treatment with Lynparza induced a 34% anti-cancer response rate for an average of nearly 8 months.
Patients with advanced ovarian cancer may wish to speak with their healthcare provider regarding their eligibility, as well as risks and benefits of treatment with Lynparza.

Reference: United States Food and Drug Administration. FDA approves Lynparza to treat advanced ovarian cancer. Available at: Accessed December 19, 2014.